Europe has 50x more immunotherapy trials than Africa.
Precision Gap
50x
Africa Model
Population-level
Europe Model
Personalised
Trials Scanned
10,000
Key Finding
Precision medicine innovation is concentrated in a geographic frontier that excludes 1.4 billion Africans from the most advanced therapeutic paradigms of the twenty-first century.
Regional Comparison
Cancer — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Immunotherapy: AF 92 vs US 3,803 (41.3x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Europe and the US are pivoting rapidly toward precision medicine — immunotherapy, targeted molecular therapy, pharmacogenomics. Africa remains within a population-level observational paradigm. The 50-fold gap in immunotherapy trials warns of a future where life-saving genomic innovations are geographically gated and inaccessible to African patients.
The Evidence 136 words · target 156
In the innovation frontier of clinical medicine, does the disparity in immunotherapy and precision medicine trials between Africa and high-income nations create a technology access crisis? This audit compared advanced therapy trial volumes using ClinicalTrials.gov keyword searches for immunotherapy (92 African versus 3,803 United States), Bayesian designs (20 versus 494), and adaptive trials (140 versus 2,986) through March 2026. Africa's immunotherapy rate of 0.39% of total trials was 41x lower than the United States rate. Precision medicine innovation is concentrated in a geographic frontier that excludes 1.4 billion Africans from the most advanced therapeutic paradigms of the twenty-first century. Without local immunotherapy and genomic trial capacity, African patients will depend indefinitely on therapies designed for European and American genomes. These findings warn of a permanent technology access crisis. Interpretation is limited by evolving precision medicine terminology.
Sentence Structure
Question
In the innovation frontier of clinical medicine, does the disparity in immunotherapy and precision medicine trials between Africa and high-income nations create a technology access crisis?
Dataset
This audit compared advanced therapy trial volumes using ClinicalTrials.gov keyword searches for immunotherapy (92 African versus 3,803 United States), Bayesian designs (20 versus 494), and adaptive trials (140 versus 2,986) through March 2026.
Method
Africa's immunotherapy rate of 0.39% of total trials was 41x lower than the United States rate.
Primary Result
Precision medicine innovation is concentrated in a geographic frontier that excludes 1.4 billion Africans from the most advanced therapeutic paradigms of the twenty-first century.
Robustness
Without local immunotherapy and genomic trial capacity, African patients will depend indefinitely on therapies designed for European and American genomes.
Interpretation
These findings warn of a permanent technology access crisis.
Boundary
Interpretation is limited by evolving precision medicine terminology.